Pneumococcal meningitis in adults: new approaches to management and prevention

  title={Pneumococcal meningitis in adults: new approaches to management and prevention},
  author={Martijn Weisfelt and Jan de Gans and Tom van der Poll and Diederik Beek},
  journal={The Lancet Neurology},
Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis
The changing epidemiology of bacterial meningitis in the United States and throughout the world is described by reviewing the global changes in etiological agents followed by specific microorganism data on the impact of the development and widespread use of conjugate vaccines.
Bacterial meningitis.
Pathophysiology of pneumococcal meningitis
It is shown that pneumococcal virulence also plays a role in the outcome of pneumococCal meningitis in patients, and the absence of a pneumitiscal arginine synthetase system is associated with favorable outcome in patients.
Drug Insight: adjunctive therapies in adults with bacterial meningitis
The pathogenesis and pathophysiology of bacterial meningitis is summarized, the evidence for and against use of the available adjunctive therapies in clinical practice are focused on, and evidence in favor of dexamethasone treatment is focused on.
Invasive Pneumococcal Infections in Finland before Routine Use of Conjugate
This study provides a comprehensive picture of the epidemiology of pneumitiscal infections in Finland before the introduction of childhood pneumococcal conjugate vaccines, focusing on disease rates, risk factors, clinical outcome, and healthcare associated infections.
Pathogenesis and Pathophysiology of Pneumococcal Meningitis
The most recent views on the pathophysiology of pneumococcal meningitis are discussed, as well as potential targets for (adjunctive) therapy.
Bacterial meningitis: a review of effective pharmacotherapy
The review presents a brief overview of key clinical and epidemiological aspects of the disease and focuses on advances in pharmacotherapeutic strategies in adult patients with bacterial meningitis in the developed world.
Invasive pneumococcal disease; a serious and preventable infection
Any infection characterized by the presence of Streptococcus pneumoniae in a body site which is usually sterile, is called invasive pneumococcal disease (IPD), and a large proportion of those serotypes responsible for IPD are covered by the current (and future) pneumococCal vaccines.
Dexamethasone in Adults with Community-Acquired Bacterial Meningitis
Bacterial meningitis in adults is a severe disease with high fatality and morbidity rates. Experimental studies have shown that the inflammatory response in the subarachnoid space is associated with


Changing epidemiology of bacterial meningitis in the United States
Emergence of antimicrobial resistance in S. pneumoniae has altered the approach to antimicrobial therapy in patients with pneumococcal meningitis, indicating the need to use preventive strategies to reduce the frequency of this serious infection.
Pathogenesis and pathophysiology of pneumococcal meningitis.
Dexamethasone in adults with bacterial meningitis
A prospective, randomized, double-blind, multicenter trial of adjuvant treatment with dexamethasone, as compared with placebo, in adults with acute bacterial meningitis.
Bacterial meningitis--a view of the past 90 years.
  • M. Swartz
  • Medicine
    The New England journal of medicine
  • 2004
The history of community-acquired bacterial meningitis arguably represents the best example of the salutary effect of the introduction of antimicrobial agents. Before the use of specific antiserums,
Bacterial meningitis in the United States in 1995. Active Surveillance Team.
Bacterial meningitis in the United States is now a disease predominantly of adults rather than of infants and young children, largely as a result of a 94 percent reduction in the number of cases of H. influenzaeMeningitis due to vaccine-related decline.
Community-Acquired Bacterial Meningitis: Risk Stratification for Adverse Clinical Outcome and Effect of Antibiotic Timing
A prognostic model was developed that stratified patients into three levels of risk (low, intermediate, and high) for adverse clinical outcome and the prediction accuracy of the prognosticmodel was assessed.